SONOSCAPE(SZ:300633) Xin Lang Cai Jing·2025-09-03 05:48Core Viewpoint - The stock of Kaili Medical has experienced a decline in trading, with a current price of 32.15 yuan per share and a market capitalization of 13.91 billion yuan, reflecting a 9.76% increase year-to-date but a recent downward trend in the last five, twenty, and sixty days [1] Financial Performance - For the first half of 2025, Kaili Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [2] - Since its A-share listing, Kaili Medical has distributed a total of 381 million yuan in dividends, with 258 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Kaili Medical was 14,300, a decrease of 1.46% from the previous period, while the average circulating shares per person increased by 1.48% to 30,244 shares [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Guangfa Medical Care Stock A, with increases in holdings compared to the previous period [3] Business Overview - Kaili Medical, established on September 27, 2002, and listed on April 6, 2017, specializes in the research, development, production, and sales of medical diagnostic and treatment equipment [1] - The company's main revenue sources are ultrasound imaging (58.07%) and endoscopes and related treatment instruments (40.90%), with other sources contributing 1.02% [1] Market Position - Kaili Medical operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept segments including in vitro diagnostics and medical devices [1]